Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas
- 25 July 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 34 (5) , 524-530
Abstract
Purpose of review: In this review we highlight the most recent studies furthering the clinical development of selinexor, a novel exportin-1 inhibitor, for the treatment of multiple myeloma and non-Hodgkin lymphomas. Recent findings: Three pivotal trials, the SADAL trial for diffuse large B-cell lymphoma, and the BOSTON and selinexor treatment of refractory myeloma trials for multiple myeloma, have recently led to the regulatory approval of selinexor monotherapy or combination regimens. They are complemented by several earlier phase clinical trials with iterative combinations, adding selinexor to novel therapies and cytotoxic chemotherapy regimens at various stages in the disease courses. In some, selinexor appears synergistic, occasionally overcoming treatment refractoriness, whereas in other situations appears additive. Consistent issues with tolerability are seen across trials, although consensus guidelines on their preemption and management have recently been adopted which may improve treatment success. While comparative data are lacking, the efficacy of selinexor-based regimens does not approach that of contemporaneous cellular and immunotherapies. Summary: Selinexor is a novel and potentially synergistic therapy for lymphoid malignancies, although requires refined supportive measures and strategies to improve its efficacy. Likely, for continued success, it will need to identify niches that complement recent advances, such as bridging to cellular therapies or maintenance thereafter.Keywords
This publication has 37 references indexed in Scilit:
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJournal of Hematology & Oncology, 2016
- XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal CancerClinical Cancer Research, 2016
- Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic ShuttlingClinical Cancer Research, 2015
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing programPediatric Blood & Cancer, 2015
- Nucleo-cytoplasmic transport as a therapeutic target of cancerJournal of Hematology & Oncology, 2014
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agentsJournal of Hematology & Oncology, 2014
- Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsSeminars in Cancer Biology, 2014
- Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer StrategyCancer Discovery, 2014
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsLeukemia, 2013